161 related articles for article (PubMed ID: 27046441)
21. Eltrombopag: a novel oral thrombopoietin receptor agonist.
Corman SL; Mohammad RA
Ann Pharmacother; 2010 Jun; 44(6):1072-9. PubMed ID: 20460556
[TBL] [Abstract][Full Text] [Related]
22. Is there a role for low-dose eltrombopag as maintenance therapy in the treatment of immune thrombocytopenia?
Vlachaki E; Sousos N; Perifanis V; Kaiafa G; Onoufriadis I; Hatzitolios A; Boura P
Acta Haematol; 2015; 133(1):78-82. PubMed ID: 25170628
[TBL] [Abstract][Full Text] [Related]
23. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
[TBL] [Abstract][Full Text] [Related]
24. Eltrombopag as steroid sparing therapy for immune thrombocytopenic purpura in systemic lupus erythematosus.
Maroun MC; Ososki R; Andersen JC; Dhar JP
Lupus; 2015 Jun; 24(7):746-50. PubMed ID: 25416695
[TBL] [Abstract][Full Text] [Related]
25. Cytokine changes in response to TPO receptor agonist treatment in primary immune thrombocytopenia.
Qu MM; Liu XN; Liu XG; Feng Q; Liu Y; Zhang X; Liu S; Zhang L; Li GS; Zhu YY; Lv MY; Peng J; Hou M
Cytokine; 2017 Apr; 92():110-117. PubMed ID: 28142109
[TBL] [Abstract][Full Text] [Related]
26. [Successful treatment of secondary graft failure after allogeneic stem cell transplantation for aplastic anemia with eltrombopag].
Takano K; Izumi T; Kawamura T; Horiuchi T; Kobayashi S; Sato K; Kimura F
Rinsho Ketsueki; 2022; 63(3):177-181. PubMed ID: 35387929
[TBL] [Abstract][Full Text] [Related]
27. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
28. Sustained response after discontinuation of short-and medium-term treatment with eltrombopag in patients with immune thrombocytopenia.
González-López TJ; Sánchez-González B; Pascual C; Arefi M; de Cabo E; Alonso A; Martín-Salces M; Jiménez-Bárcenas R; Calbacho M; Galan P; Barez A; González-Porras JR
Platelets; 2015; 26(1):83-6. PubMed ID: 24499036
[TBL] [Abstract][Full Text] [Related]
29. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.
Kuter DJ; Macahilig C; Grotzinger KM; Poston SA; Wang PF; Dawson KL; Ward M
Int J Hematol; 2015 Mar; 101(3):255-63. PubMed ID: 25586660
[TBL] [Abstract][Full Text] [Related]
30. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice.
González-López TJ; Alvarez-Román MT; Pascual C; Sánchez-González B; Fernández-Fuentes F; Jarque I; Pérez-Rus G; Pérez-Crespo S; Bernat S; Hernández-Rivas JA; Andrade MM; Cortés M; Gómez-Nuñez M; Olivera P; Martínez-Robles V; Fernández-Rodríguez A; Fuertes-Palacio MA; Fernández-Miñano C; de Cabo E; Fisac R; Aguilar C; Bárez A; Peñarrubia MJ; García-Frade LJ; González-Porras JR
Eur J Haematol; 2016 Sep; 97(3):297-302. PubMed ID: 26709028
[TBL] [Abstract][Full Text] [Related]
31. Use of eltrombopag after romiplostim in primary immune thrombocytopenia.
González-Porras JR; Mingot-Castellano ME; Andrade MM; Alonso R; Caparrós I; Arratibel MC; Fernández-Fuertes F; Cortti MJ; Pascual C; Sánchez-González B; Bernat S; Fuertes-Palacio MA; Vázquez-Paganini JA; Olivera PE; Alvarez-Román MT; Jarque I; Cortés M; Martínez-Robles V; Díaz-Gálvez FJ; Calbacho M; Fernández-Miñano C; Garcia-Frade J; González-López TJ
Br J Haematol; 2015 Apr; 169(1):111-6. PubMed ID: 25521630
[TBL] [Abstract][Full Text] [Related]
32. Outcome following second allogeneic hematopoietic cell transplantation: A single-center experience.
Aljasem HA; Messner HA; Lipton JH; Kim DDH; Viswabandya A; Thyagu S; Deotare U; Michelis FV
Eur J Haematol; 2018 Mar; 100(3):308-314. PubMed ID: 29240253
[TBL] [Abstract][Full Text] [Related]
33. Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.
Garnock-Jones KP
BioDrugs; 2011 Dec; 25(6):401-4. PubMed ID: 22050343
[TBL] [Abstract][Full Text] [Related]
34. Eltrombopag for the Treatment of Poor Graft Function Following Haematopoietic Cell Transplantation: Real-Life Data.
Kırcalı E; Cengiz Seval G; Öztürk C; Yılmaz H; Koyun D; Civriz Bozdağ S; Toprak SK; Topçuoğlu P; Arslan Ö; Özcan M; Demirer T; İlhan O; Gürman G; Beksaç M; Kurt Yüksel M
Balkan Med J; 2023 Jan; 40(1):51-56. PubMed ID: 36571427
[TBL] [Abstract][Full Text] [Related]
35. Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study.
Giammarco S; Sica S; Chiusolo P; Laurenti L; Sorá F; Martino M; Metafuni E; Busca A; Risitano A; Vallejo C; Bacigalupo A
Int J Hematol; 2021 Aug; 114(2):228-234. PubMed ID: 33886103
[TBL] [Abstract][Full Text] [Related]
36. Eltrombopag as first-line treatment for thrombocytopenia among paediatric patients after allogeneic haematopoietic stem cell transplantation.
Qiu KY; Liao XY; Huang K; Wu RH; Xu HG; Xu LH; Li Y; Weng WJ; Zhou DH; Fang JP
Br J Clin Pharmacol; 2021 Apr; 87(4):2023-2031. PubMed ID: 33080064
[TBL] [Abstract][Full Text] [Related]
37. Eltrombopag in the management of aplastic anaemia: real-world experience in a non-trial setting.
Hwang YY; Gill H; Chan TSY; Leung GMK; Cheung CYM; Kwong YL
Hematology; 2018 Aug; 23(7):399-404. PubMed ID: 29303047
[TBL] [Abstract][Full Text] [Related]
38. Eltrombopag for the Treatment of Allogeneic Hematopoietic Stem Cell Transplantation-Related Poor Graft Function.
Arslan Davulcu E; Akad Soyer N; Vural F
Cureus; 2023 Sep; 15(9):e44555. PubMed ID: 37790070
[TBL] [Abstract][Full Text] [Related]
39. Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: A retrospective collaborative survey involving 4 Spanish centres.
Lakhwani S; Perera M; Fernández-Fuertes F; Ríos de Paz MA; Torres M; Raya JM; Hernández MT
Eur J Haematol; 2017 Oct; 99(4):372-377. PubMed ID: 28759125
[TBL] [Abstract][Full Text] [Related]
40. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia.
González-López TJ; Pascual C; Álvarez-Román MT; Fernández-Fuertes F; Sánchez-González B; Caparrós I; Jarque I; Mingot-Castellano ME; Hernández-Rivas JA; Martín-Salces M; Solán L; Beneit P; Jiménez R; Bernat S; Andrade MM; Cortés M; Cortti MJ; Pérez-Crespo S; Gómez-Núñez M; Olivera PE; Pérez-Rus G; Martínez-Robles V; Alonso R; Fernández-Rodríguez A; Arratibel MC; Perera M; Fernández-Miñano C; Fuertes-Palacio MA; Vázquez-Paganini JA; Gutierrez-Jomarrón I; Valcarce I; de Cabo E; Sainz A; Fisac R; Aguilar C; Paz Martínez-Badas M; Peñarrubia MJ; Calbacho M; de Cos C; González-Silva M; Coria E; Alonso A; Casaus A; Luaña A; Galán P; Fernández-Canal C; Garcia-Frade J; González-Porras JR
Am J Hematol; 2015 Mar; 90(3):E40-3. PubMed ID: 25400215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]